Connection

JEFFREY J MOLLDREM to Cytotoxicity, Immunologic

This is a "connection" page, showing publications JEFFREY J MOLLDREM has written about Cytotoxicity, Immunologic.
Connection Strength

1.050
  1. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011 Apr 21; 117(16):4262-72.
    View in: PubMed
    Score: 0.317
  2. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol. 2018; 9:3153.
    View in: PubMed
    Score: 0.137
  3. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
    View in: PubMed
    Score: 0.137
  4. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
    View in: PubMed
    Score: 0.130
  5. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy. 2010 Dec; 12(8):1056-62.
    View in: PubMed
    Score: 0.077
  6. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003 Mar; 111(5):639-47.
    View in: PubMed
    Score: 0.046
  7. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000 Sep; 6(9):1018-23.
    View in: PubMed
    Score: 0.038
  8. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997 Oct 01; 90(7):2529-34.
    View in: PubMed
    Score: 0.031
  9. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996 Oct 01; 88(7):2450-7.
    View in: PubMed
    Score: 0.029
  10. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol. 1996 Jun; 93(3):606-12.
    View in: PubMed
    Score: 0.029
  11. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother. 2016 06; 65(6):741-51.
    View in: PubMed
    Score: 0.028
  12. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
    View in: PubMed
    Score: 0.022
  13. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother. 2010 Nov-Dec; 33(9):975-82.
    View in: PubMed
    Score: 0.019
  14. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 May; 19(10):989-99.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.